Vaxxas announces promising results in skin patch vaccine trial: A revolution in immunization
Vaxxas, a clinical-stage biotechnology company, has achieved a significant milestone in vaccine delivery technology. The company's innovative high-density microarray patch (HD-MAP) technology, which enables vaccines ... Read More
Vaxxas opens Vaxxas Biomedical Facility in Brisbane to manufacture vaccines
Vaxxas, a clinical-stage biotechnology company, has announced the opening of Vaxxas Biomedical Facility, its first manufacturing facility in Brisbane, Queensland. The 60,000 square feet facility ... Read More